ArticleCirculation2009
Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community.
Article in Circulation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Risk models to predict hypertension: a systematic review.PloS one · 2013Pooled it
- Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation.Journal of the American Heart Association · 2020Trial
- Extracellular matrix in vascular homeostasis and disease.Nature reviews. Cardiology · 2025Review
- Time to Change Our Viewpoints to Assess Renal Risks in Patients with Solitary Kidneys beyond Traditional Approaches?Journal of clinical medicine · 2023Article
- Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis.Healthcare (Basel, Switzerland) · 2022Review
- Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder.Frontiers in psychiatry · 2021Article
- The reduction of apnea-hypopnea duration ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in a rat model of obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2019Article
- Tissue Inhibitor of Matrix Metalloproteinase 1 Increases With Ageing and Can Be Associated With Stroke - Nested Case-Control Study.Circulation reports · 2019Article
- Mechanisms of cardiac collagen deposition in experimental models and human disease.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease.Journal of the American Heart Association · 2019Article
- Matrix Metalloproteinase-9 Is a Predictive Factor for Systematic Hypertension and Heart Dysfunction in Patients with Obstructive Sleep Apnea Syndrome.BioMed research international · 2018Article
- Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.Trends in cardiovascular medicine · 2017Review
- Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.Progress in molecular biology and translational science · 2017Review
- Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes.International journal of molecular sciences · 2016Article
- Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.Arquivos brasileiros de cardiologia · 2015Article
- Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults.Diabetology & metabolic syndrome · 2015Article
- Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.Circulation. Arrhythmia and electrophysiology · 2014Article
- Study of the correlations among some parameters of the oxidative status, gelatinases, and their inhibitors in a group of subjects with metabolic syndrome.Mediators of inflammation · 2014Article
- Direct Renin Inhibitor Attenuates Left Ventricular Remodeling in Post-Myocardial Infarction Heart Failure Mice.Acta Cardiologica Sinica · 2013Article
- Is isolated systolic hypertension worse than combined systolic/diastolic hypertension?Journal of clinical hypertension (Greenwich, Conn.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundBiomarkers of extracellular matrix remodeling are associated with prevalent hypertension in cross-sectional studies, but their relations to longitudinal changes in blood pressure (BP) and hypertension incidence are unknown. METHODS AND
resultsWe evaluated 595 nonhypertensive Framingham Offspring Study participants (mean age 55 years; 360 women) without prior heart failure or myocardial infarction who underwent routine measurements of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1), metalloproteinase-9 (MMP-9), and procollagen III N-terminal peptide. We related plasma TIMP-1, procollagen III N-terminal peptide, and MMP-9 to the incidence of hypertension and progression of BP by >or=1 category (defined on the basis of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). On follow-up (4 years), 81 participants (51 women) developed hypertension, and 198 (114 women) progressed to a higher BP category. In multivariable models, a 1-SD increment of log-TIMP-1 was associated with a 50% higher incidence of hypertension (95% CI 1.08 to 2.08) and a 21% (95% CI 1.00 to 1.47) higher risk of BP progression. Individuals in the top TIMP-1 tertile had a 2.15-fold increased risk of hypertension (95% CI 0.99 to 4.68) and 1.68-fold (95% CI 1.05 to 2.70) increased risk of BP progression relative to the lowest tertile. Individuals with detectable MMP-9 had a 1.97-fold higher risk of BP progression (95% CI 1.06 to 3.64) than those with undetectable levels. Plasma procollagen III N-terminal peptide was not associated with hypertension incidence or BP progression.
conclusionsIn the present community-based sample, higher TIMP-1 and MMP-9 concentrations were associated with BP progression on follow-up. Additional studies are warranted to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.